These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 25047938)
21. Probing the pore drug binding site of microtubules with fluorescent taxanes: evidence of two binding poses. Barasoain I; García-Carril AM; Matesanz R; Maccari G; Trigili C; Mori M; Shi JZ; Fang WS; Andreu JM; Botta M; Díaz JF Chem Biol; 2010 Mar; 17(3):243-53. PubMed ID: 20338516 [TBL] [Abstract][Full Text] [Related]
22. Designing and Testing of Novel Taxanes to Probe the Highly Complex Mechanisms by Which Taxanes Bind to Microtubules and Cause Cytotoxicity to Cancer Cells. St George M; Ayoub AT; Banerjee A; Churchill CD; Winter P; Klobukowski M; Cass CE; Ludueña RF; Tuszynski JA; Damaraju S PLoS One; 2015; 10(6):e0129168. PubMed ID: 26052950 [TBL] [Abstract][Full Text] [Related]
23. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Giannakakou P; Gussio R; Nogales E; Downing KH; Zaharevitz D; Bollbuck B; Poy G; Sackett D; Nicolaou KC; Fojo T Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2904-9. PubMed ID: 10688884 [TBL] [Abstract][Full Text] [Related]
25. Effects of C7 substitutions in a high affinity microtubule-binding taxane on antitumor activity and drug transport. Xiao X; Wu J; Trigili C; Chen H; Chu JW; Zhao Y; Lu P; Sheng L; Li Y; Sharom FJ; Barasoain I; Diaz JF; Fang WS Bioorg Med Chem Lett; 2011 Aug; 21(16):4852-6. PubMed ID: 21764308 [TBL] [Abstract][Full Text] [Related]
26. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Dumontet C; Jordan MA; Lee FF Mol Cancer Ther; 2009 Jan; 8(1):17-25. PubMed ID: 19139109 [TBL] [Abstract][Full Text] [Related]
27. Effects of novel taxanes SB-T-1213 and IDN5109 on tubulin polymerization and mitosis. Jordan MA; Ojima I; Rosas F; Distefano M; Wilson L; Scambia G; Ferlini C Chem Biol; 2002 Jan; 9(1):93-101. PubMed ID: 11841942 [TBL] [Abstract][Full Text] [Related]
28. Elucidating the mechanism of action of the clinically approved taxanes: a comprehensive comparison of local and allosteric effects. Churchill CD; Klobukowski M; Tuszynski JA Chem Biol Drug Des; 2015 Nov; 86(5):1253-66. PubMed ID: 26032329 [TBL] [Abstract][Full Text] [Related]
29. Therapeutic strategies to overcome taxane resistance in cancer. Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261 [TBL] [Abstract][Full Text] [Related]
30. Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers. Wang R; Wang H; Wang Z J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287508 [TBL] [Abstract][Full Text] [Related]
31. Molecular recognition of peloruside A by microtubules. The C24 primary alcohol is essential for biological activity. Pera B; Razzak M; Trigili C; Pineda O; Canales A; Buey RM; Jiménez-Barbero J; Northcote PT; Paterson I; Barasoain I; Díaz JF Chembiochem; 2010 Aug; 11(12):1669-78. PubMed ID: 20665616 [TBL] [Abstract][Full Text] [Related]
32. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells. Wang H; Vo T; Hajar A; Li S; Chen X; Parissenti AM; Brindley DN; Wang Z BMC Cancer; 2014 Jan; 14():37. PubMed ID: 24447372 [TBL] [Abstract][Full Text] [Related]
34. Medicinal chemistry and chemical biology of new generation taxane antitumor agents. Ojima I; Geney R; Ungureanu IM; Li D IUBMB Life; 2002; 53(4-5):269-74. PubMed ID: 12121008 [TBL] [Abstract][Full Text] [Related]
35. Farnesyltransferase inhibitors reverse taxane resistance. Marcus AI; O'Brate AM; Buey RM; Zhou J; Thomas S; Khuri FR; Andreu JM; Díaz F; Giannakakou P Cancer Res; 2006 Sep; 66(17):8838-46. PubMed ID: 16951201 [TBL] [Abstract][Full Text] [Related]
36. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents. Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019 [TBL] [Abstract][Full Text] [Related]
37. βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells. Kanakkanthara A; Northcote PT; Miller JH Mol Cancer Ther; 2012 Feb; 11(2):393-404. PubMed ID: 22180309 [TBL] [Abstract][Full Text] [Related]
39. Recent advances in the new generation taxane anticancer agents. Geney R; Chen J; Ojima I Med Chem; 2005 Mar; 1(2):125-39. PubMed ID: 16787308 [TBL] [Abstract][Full Text] [Related]
40. Effects of eribulin on microtubule binding and dynamic instability are strengthened in the absence of the βIII tubulin isotype. Wilson L; Lopus M; Miller HP; Azarenko O; Riffle S; Smith JA; Jordan MA Biochemistry; 2015 Oct; 54(42):6482-9. PubMed ID: 26435331 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]